Literature DB >> 8526237

Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients.

A Chatterjee1, M Chakos, A Koreen, S Geisler, B Sheitman, M Woerner, J M Kane, J Alvir, J A Lieberman.   

Abstract

OBJECTIVE: This study assessed the prevalence of extrapyramidal signs and spontaneous dyskinesia in neuroleptic-naive, first-episode schizophrenic patients and examined the clinical correlates.
METHOD: In a prospective study of the psychobiology of schizophrenia, the authors examined 89 neuroleptic-naive patients for the presence of extrapyramidal signs by using the Simpson-Angus Rating Scale and for dyskinesia by using the Tardive Dyskinesia Rating Scale.
RESULTS: Fifteen patients (16.9%) had extrapyramidal signs, but only one had spontaneous dyskinesia at baseline. Presence of extrapyramidal signs was correlated with more negative symptoms and poorer treatment outcome that was reflected in a longer time to and lower level of remission. There was no correlation of spontaneous extrapyramidal signs with age of patient, age at onset of psychotic symptoms, or baseline psychopathology. There was no difference between patients with and without spontaneous extrapyramidal signs in terms of the subsequent development of persistent tardive dyskinesia, but the patients with spontaneous extrapyramidal signs were more likely to develop parkinsonian side effects after 8 weeks of antipsychotic treatment.
CONCLUSIONS: Extrapyramidal signs are present in a proportion of neuroleptic-naive, first-episode schizophrenic patients, which suggests an involvement of these signs in the schizophrenic process that probably reflects basal ganglia pathology. The presence of spontaneous extrapyramidal signs seems to have prognostic significance insofar as it is linked to a poorer outcome and longer time to remission. Spontaneous dyskinesia appears to be a relatively rare finding.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8526237     DOI: 10.1176/ajp.152.12.1724

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  39 in total

1.  The field of schizophrenia: strengths, weaknesses, opportunities, and threats.

Authors:  John M Kane; Barbara Cornblatt; Christoph U Correll; Terry Goldberg; Todd Lencz; Anil K Malhotra; Delbert Robinson; Philip Szeszko
Journal:  Schizophr Bull       Date:  2011-11-18       Impact factor: 9.306

2.  Tardive dyskinesia: therapeutic options for an increasingly common disorder.

Authors:  Leslie J Cloud; Deepti Zutshi; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

3.  Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease.

Authors:  Paula Scalzo; Arthur Kümmer; Thales Lage Bretas; Francisco Cardoso; Antônio Lúcio Teixeira
Journal:  J Neurol       Date:  2009-10-22       Impact factor: 4.849

4.  Characterization of spontaneous Parkinsonism in drug-naive patients with nonaffective psychotic disorders.

Authors:  Victor Peralta; Virginia Basterra; Maria S Campos; Elena García de Jalón; Lucía Moreno-Izco; Manuel J Cuesta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-05-28       Impact factor: 5.270

Review 5.  Guidelines for the Pharmacotherapy of Schizophrenia in Adults.

Authors:  Gary Remington; Donald Addington; William Honer; Zahinoor Ismail; Thomas Raedler; Michael Teehan
Journal:  Can J Psychiatry       Date:  2017-07-13       Impact factor: 4.356

Review 6.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

7.  Extrapyramidal examinations in psychiatry.

Authors:  Richard D Sanders; Paulette Marie Gillig
Journal:  Innov Clin Neurosci       Date:  2012-07

8.  Detection, Assessment, and Management of Schizophrenia in an Andean Population of South America: Parkinsonism Testing and Transcranial Ultrasound as Preventive Tools.

Authors:  Mara Balda; Maria Calvó; Eduardo Padilla; Gonzalo Guerrero; Juan Molina; Nestor V Florenzano; Danielle Kamis; Javier I Escobar; C Robert Cloninger; Gabriel de Erausquin
Journal:  Focus (Am Psychiatr Publ)       Date:  2015

9.  Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia.

Authors:  Stefan Gebhardt; Fabian Härtling; Markus Hanke; Frank M Theisen; Richard von Georgi; Phillip Grant; Markus Mittendorf; Matthias Martin; Christian Fleischhaker; Eberhard Schulz; Helmut Remschmidt
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-09-14       Impact factor: 4.785

10.  Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis.

Authors:  Jeroen P F Koning; Diederik E Tenback; Jim van Os; André Aleman; René S Kahn; Peter N van Harten
Journal:  Schizophr Bull       Date:  2008-11-05       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.